New Drug Futures (Respiration)
Products that could change the Pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the respiratory sector. The report includes unique sales forecasts by major product. | |
| Keywords: The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 ke | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 19th May 2006
Contents:
CURRENT MARKET SIZE . 1
ADDRESSABLE PATIENT POPULATION 3
CURRENT TREATMENTS 4
Third-line therapies 5
RESPIRATORY SALES DRIVERS 7
RESPIRATORY SALES BREAKERS 9
FUTURE TREATMENTS 10
MARKET DYNAMICS - WINNERS & LOSERS 15
KEY DRUGS LAUNCHES BY 2010 16
KEY EVALUATION CRITERIA 17
KEY RESPIRATORY DRUG LAUNCHES BY 2010 18
Allermist (GlaxoSmithkline) 18
Novelty/rationale for mechanism of action 18
Proof of concept/clinical data 18
Management/clinical expertise 18
Competition within the marketplace/gaining share of voice 18
Risks associated with developing a drug within a therapeutic class 19
Filings and approval 19
Sales forecasts and assumptions 19
Competitor Ratio Analysis 20
Novelty/rationale for mechanism of action 20
Proof of concept/clinical data 20
Management/clinical expertise 21
Competition within the marketplace/gaining share of voice 21
Risks associated with developing a drug within a therapeutic class 22
Filings and approval 22
Sales forecasts and assumptions 23
Competitor Ratio Analysis 24
Ariflo (GSK) 24
Novelty/rationale for mechanism of action 24
Proof of concept/clinical data 24
Management/clinical expertise 24
Competition within the marketplace/gaining share of voice 25
Risks associated with developing a drug within a therapeutic class 25
Filings and approval 25
Sales forecasts and assumptions 26
Competitor Ratio Analysis 26
Asmanex (Schering-Plough) 26
Novelty/rationale for mechanism of action 26
Proof of concept/clinical data 27
Management/clinical expertise 27
Competition within the marketplace/gaining share of voice 27
Risks associated with developing a drug within a therapeutic class 27
Filings and approval 27
Sales forecasts and assumptions 28
Competitor Ratio Analysis 28
Daxas (Altana) 28
Novelty/rationale for mechanism of action 28
Proof of concept/clinical data 29
RATIO/M2-112 29
RECORD Study 30
PEGASUS1 Study 30
PRIME Study 30
ROMEO Study 30
Management/clinical expertise 30
Competition within the marketplace/gaining share of voice 31
Risks associated with developing a drug within a therapeutic class 31
Filings and approval 31
Sales forecasts and assumptions 32
Competitor Ratio Analysis 32
GSK 159797 (GSK/Theravance) 33
Novelty/rationale for mechanism of action 33
Proof of concept/clinical data 33
Management/clinical expertise 33
Competition within the marketplace/gaining share of voice 33
Risks associated with developing a drug within a therapeutic class 34
Filings and approval 34
Sales forecasts and assumptions 34
Competitor Ratio Analysis 35
Mepolizumab (GlaxoSmithkline) 35
Novelty/rationale for mechanism of action 35
Proof of concept/clinical data 35
Management/clinical expertise 36
Competition within the marketplace/gaining share of voice 36
Risks associated with developing a drug within a therapeutic class 36
Filings and approval 36
Sales forecasts and assumptions 36
Competitor Ratio Analysis 37
NVA237 (Novartis/Vactura/Arakis) 37
Novelty/rationale for mechanism of action 37
Proof of concept/clinical data 37
Management/clinical expertise 37
Competition within the marketplace/gaining share of voice 37
Risks associated with developing a drug within a therapeutic class 38
Filings and approval 38
Sales forecasts and assumptions 38
Competitor Ratio Analysis 39
QAB149 (Novartis) 39
Novelty/rationale for mechanism of action 39
Proof of concept/clinical data 39
Management/clinical expertise 39
Competition within the marketplace/gaining share of voice 39
Risks associated with developing a drug within a therapeutic class 40
Filings and approval 41
Sales forecasts and assumptions 41
Competitor Ratio Analysis 41
Symbicort (AstraZeneca) 42
Novelty/rationale for mechanism of action 42
Proof of concept/clinical data 42
Single inhaler Therapy (SiT): 42
Variable dosing Symbicort more effective than fixed dosing Advair: 42
Adjustable dosing more cost effective than fixed dosing in asthma treatment42
Management/clinical expertise 43
Competition within the marketplace/gaining share of voice 43
Risks associated with developing a drug within a therapeutic class 44
Filings and approval 44
Sales forecasts and assumptions 44
Competitor Ratio Analysis 45
Xolair (Novartis) 45
Novelty/rationale for mechanism of action 45
Proof of concept/clinical data 45
Management/clinical expertise 46
Competition within the marketplace/gaining share of voice 46
Risks associated with developing a drug within a therapeutic class 46
Filings and approval 46
Sales forecasts and assumptions 46
Competitor Ratio Analysis 47
COMPETITOR RATIO ANALYSIS SUMMARY 48
COMPETITOR RATIO ANALYSIS – DRUGS 49
COMPETITOR RATIO ANALYSIS - COMPANIES 51